SSY GROUP (02005.HK): Wins NMPA approval for Letermovir Injection, deemed to have passed consistency evaluation

NewTimeSpace News: On 10 September 2026, SSY Group Limited (stock code: 02005) announced that the Group has obtained the drug production registration approval from China's National Medical Products Administration for Letermovir Injection (12ml: 240mg), classified as a Category 4 chemical drug and deemed to have passed the consistency evaluation.

According to the announcement, Letermovir Injection is primarily indicated for prophylaxis of cytomegalovirus (CMV) infection and CMV disease in adult recipients who are CMV-seropositive and undergoing allogeneic hematopoietic stem cell transplantation. The product is to be used in combination with a base infusion during the perioperative period of hematopoietic stem cell transplantation.

SSY Group stated that, leveraging its existing strength in base infusions, the Group has been continuously refining its therapeutic injection product pipeline, and this approval further enriches the Group's perioperative product portfolio.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.